submit to the journals
Psychiatric Disorders:FEATURED VIDEOS
Leading the Debate on the Advances in Healthcare
Psychiatric Disorders:FEATURED Articles
flipper_slider
Pharmacological Treatment of Schizophrenia
European Neurological Review, 2006;6(1):93-94 DOI: http://doi.org/10.17925/ENR.2006.00.01.93
The Relationship Between Attention-deficit–Hyperactivity Disorder and Restless Legs Syndrome
European Neurological Review, 2008;3(1):111-114 DOI: http://doi.org/10.17925/ENR.2008.03.01.111
Niemann-Pick Disease Type C in Adulthood – A Psychiatric and Neurological Disorder
European Neurological Review, 2010;5(1):83-87 DOI: http://doi.org/10.17925/ENR.2010.05.01.83
Editor's choice
US Neurology. 2018;14(2):78–9 DOI: https://doi.org/10.17925/USN.2018.14.2.78
US Neurology. 2018;14(Suppl. 1):2–7
Psychiatric Disorders: Latest Articles
US Neurology. 2018;14(2):78–9 DOI: https://doi.org/10.17925/USN.2018.14.2.78
US Neurology. 2018;14(Suppl. 1):2–7
US Neurology, 2017;13(2):78–81 DOI: https://doi.org/10.17925/USN.2017.13.02.78
European Neurological Review, 2016;11(1): 20–1 DOI: https://doi.org/10.17925/ENR.2016.11.01.20
US Neurology, 2016;12(2):93–7 DOI: https://doi.org/10.17925/USN.2016.12.02.93
Psychiatric Disorders:FEATURED VIDEOS
Editor's choice
The goal of functional neuroimaging is to assist in the development of targeted treatments for psychiatric illness.
Daniel Kremens (Sidney Kimmel Medical College, Thomas Jefferson University) discusses his recently published article co-authored with Stuart Isaacson, entitled: Treatment Advances in Parkinson’s Disease Psychosis—Transforming the Standard of Care for Hallucinations and Delusions. In this report, they explore the pathophysiology, symptomology, diagnosis and impact of Parkinson's disease psychosis (PDP), the role of serotonin signaling within PDP, and examine the current standard of care for treatment for the condition. The full article can be viewed here.
Questions
1. How does Parkinson’s disease psychosis (PDP) differ from other psychotic disorders? (0:11)
2. What are the pathophysiological mechanisms underlying the development of PDP? (1:12)
3. What is the major limitation of atypical antispychotic drugs in treating patients with PDP? (2:32)
4. What clinical evidence supports the use of pimavenserin for PDP? (3:29)
Speaker disclosures: Daniel Kremens has worked as a consultant for ACADIA, Teva, GE Healthcare, US WorldMeds, Impax, UCB, Kyowa, Acorda, Sunovion, St. Jude Medical, Adamas, Neurocrine and Prexton Therapeutics; received speaker’s honoraria for ACADIA, Teva, US WorldMeds, Impax, and UCB; and received research funding from Civitas and Enterin.
Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018, with support from ACADIA Pharmaceuticals Inc.
Psychiatric Disorders:Latest Videos
Video List based on Category on Node Page
Latest Videos
Daniel Kremens (Sidney Kimmel Medical College, Thomas Jefferson University) discusses his recently published article co-authored with Stuart Isaacson, entitled: Treatment Advances in Parkinson’s Disease Psychosis—Transforming the Standard of Care for Hallucinations and Delusions. In this...
The goal of functional neuroimaging is to assist in the development of targeted treatments for psychiatric illness.
